Table 1.
Effect of pharmacological inhibitors on neurite outgrowth
| Neurite length (μm) | ||||
|---|---|---|---|---|
| Inhibitor treatment | Target | Concentration | Inhibitor alone | Inhibitor+NGF |
| Exp 1 | ||||
| None | 115.2±5.4 | 233.3±5.9 | ||
| LY294002 | PI3K | 1 μM | 117.7±5.2 | 234.8±7.5 |
| 5 μM | 109.2±3.3 | 252.6±8.5 | ||
| PD98059 | ERK | 10 μM | 116.7±4.0 | 230.7±7.2 |
| U0126 | ERK | 10 μM | 97.5a±3.0 | 198.2b±10.1 |
| SB203580 | p38 | 10 μM | 124.2±4.3 | 232.2±7.1 |
| MAPK | ||||
| Exp 2 | ||||
| None | 105.0±3.3 | 202.1±6.8 | ||
| Lovastatin | Ras | 5 μg ml−1 | 115.5±2.7 | 171.2±5.3 |
| GW5074 | Raf | 1 μM | 110.5±3.3 | 202.5±8.6 |
| U73343 | PLC- | 1 μM | 108.2±2.9 | 193.0±6.9 |
| U73122 | PLC | 1 μM | 106.1±2.3 | 180.1±5.7 |
| Ro 31-8220 | PKC | 1 μM | 109.4±3.1 | 199.0±6.6 |
| Go6983 | PKC | 1 μM | 103.8±2.5 | 183.1±9.3 |
| SP600125 | JNK | 1 μM | 114.5±3.1 | 200.8±5.8 |
| H-89 | PKA | 5 μM | 118.7±3.5 | 270.6b±8.6 |
| Rp-cAMPs | PKA | 10 μM | 126.3±4.7 | 260.5b±9.7 |
| PD98059 | ERK | 20 μM | ND | 145.4b±5.4 |
| U0126 | ERK | 20 μM | ND | 112.8b±3.8 |
a
Significantly different than no inhibitor treatment (P<0.05). Significantly different than NGF alone.
b
(P<0.05). ND, not determined.
Data represent length of the longest neurite on SH-SY5Y human neuroblastoma cells treated with or without NGF for 96 h, with inhibitor treatments during the last 48 h (N=3).